Pheon Therapeutics is an Antibody Drug Conjugate (ADC) specialist developing a pipeline of monotherapies for novel targets and/or with novel payloads. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/28/22 | $68,000,000 | Series A |
Atlas Venture Forbion Capital Partners Research Corporation Technologies | undisclosed |
